Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Raul D Santos is active.

Publication


Featured researches published by Raul D Santos.


PLOS ONE | 2012

Phosphorus Is Associated with Coronary Artery Disease in Patients with Preserved Renal Function

Ana L.E. Cancela; Raul D Santos; Silvia Maria de Oliveira Titan; Patricia Taschner Goldenstein; Carlos Eduardo Rochitte; Pedro A. Lemos; Luciene Machado do Reis; Fabiana G. Graciolli; Vanda Jorgetti; Rosa Maria Affonso Moysés

High serum phosphorus levels have been associated with mortality and cardiovascular events in patients with chronic kidney disease and in the general population. In addition, high phosphorus levels have been shown to induce vascular calcification and endothelial dysfunction in vitro. The aim of this study was to evaluate the relation of phosphorus and coronary calcification and atherosclerosis in the setting of normal renal function. This was a cross-sectional study involving 290 patients with suspected coronary artery disease and undergoing elective coronary angiography, with a creatinine clearance >60 ml/min/1.73 m2. Coronary artery obstruction was assessed by the Friesinger score and coronary artery calcification by multislice computed tomography. Serum phosphorus was higher in patients with an Agatston score >10 than in those with an Agatston score ≤10 (3.63±0.55 versus 3.49±0.52 mg/dl; p = 0.02). In the patients with Friesinger scores >4, serum phosphorus was higher (3.6±0.5 versus 3.5±0.6 mg/dl, p = 0.04) and median intact fibroblast growth factor 23 was lower (40.3 pg/ml versus 45.7 pg/ml, p = 0.01). Each 0.1-mg/dl higher serum phosphate was associated with a 7.4% higher odds of having a Friesinger score >4 (p = 0.03) and a 6.1% greater risk of having an Agatston score >10 (p = 0.01). Fibroblast growth factor 23 was a negative predictor of Friesinger score (p = 0.002). In conclusion, phosphorus is positively associated with coronary artery calcification and obstruction in patients with suspected coronary artery disease and preserved renal function.


Diabetology & Metabolic Syndrome | 2014

Diabetes and cardiovascular disease: from evidence to clinical practice – position statement 2014 of Brazilian Diabetes Society

Marcello Casaccia Bertoluci; Augusto Pimazoni-Netto; Antônio Carlos Pires; Antonio Eduardo Pereira Pesaro; Beatriz D'Agord Schaan; Bruno Caramelli; Carisi Anne Polanczyk; Carlos Vicente Serrano Júnior; Danielle Menosi Gualandro; Domingos Malerbi; Emílio Hideyuki Moriguchi; Flavio Antonio de Oliveira Borelli; João Eduardo Nunes Salles; José Mariani Júnior; Luis E. Rohde; Luis Henrique Santos Canani; Luiz Antonio Machado César; Marcos Antonio Tambascia; Maria Tereza Zanella; Miguel Gus; Rafael Selbach Scheffel; Raul D Santos

There is a very well known correlation between diabetes and cardiovascular disease but many health care professionals are just concerned with glycemic control, ignoring the paramount importance of controlling other risk factors involved in the pathogenesis of serious cardiovascular diseases. This Position Statement from the Brazilian Diabetes Society was developed to promote increased awareness in relation to six crucial topics dealing with diabetes and cardiovascular disease: Glicemic Control, Cardiovascular Risk Stratification and Screening Coronary Artery Disease, Treatment of Dyslipidemia, Hypertension, Antiplatelet Therapy and Myocardial Revascularization. The issue of what would be the best algorithm for the use of statins in diabetic patients received a special attention and a new Brazilian algorithm was developed by our editorial committee. This document contains 38 recommendations which were classified by their levels of evidence (A, B, C and D). The Editorial Committee included 22 specialists with recognized expertise in diabetes and cardiology.


Arquivos Brasileiros De Cardiologia | 2014

Fatty Acid and Cholesterol Concentrations in Usually Consumed Fish in Brazil

Carlos Scherr; Ana Carolina Moron Gagliardi; Marcio H. Miname; Raul D Santos

Background Several studies have demonstrated clinical benefits of fish consumption for the cardiovascular system. These effects are attributed to the increased amounts of polyunsaturated fatty acids in these foods. However, the concentrations of fatty acids may vary according to region. Objective The goal of this study was to determine the amount of,cholesterol and fatty acids in 10 Brazilian fishes and in a non-native farmed salmon usually consumed in Brazil. Methods The concentrations of cholesterol and fatty acids, especially omega-3, were determined in grilled fishes. Each fish sample was divided in 3 sub-samples (chops) and each one was extracted from the fish to minimize possible differences in muscle and fat contents. Results The largest cholesterol amount was found in white grouper (107.6 mg/100 g of fish) and the smallest in badejo (70 mg/100 g). Omega-3 amount varied from 0.01 g/100 g in badejo to 0.900 g/100 g in weakfish. Saturated fat varied from 0.687 g/100 g in seabass to 4.530 g/100 g in filhote. The salmon had the greatest concentration of polyunsaturated fats (3.29 g/100 g) and the highest content of monounsaturated was found in pescadinha (5.98 g/100 g). Whiting and boyfriend had the best omega-6/omega 3 ratios respectively 2.22 and 1.19, however these species showed very little amounts of omega-3. Conclusion All studied Brazilian fishes and imported salmon have low amounts of saturated fat and most of them also have low amounts of omega-3.


Food Science and Technology International | 2010

Effects of defatted amaranth (Amaranthus caudatus L.) snacks on lipid metabolism of patients with moderate hypercholesterolemia

Rosa Nilda Chávez-Jáuregui; Raul D Santos; Alessandra Alaniz Macedo; Ana Paula Marte Chacra; Tania Leme da Rocha Martinez; José Alfredo Gomes Arêas

We evaluated the effects of defatted amaranth ( Amaranthus caudatus L.) snacks on plasma lipids in moderate hypercholesterolemic patients. Twenty-two subjects [30−65 years old), 11 males, with total cholesterol (TC) ≥ 240 mg.dL –1 , low-density cholesterol (LDL−c) 160−190 mg.dL –1 and plasma triglycerides (TG) < 400 mg.dL –1 ] were randomized in a double blind clinical trial to receive an amaranth snack (50 g/day) or equivalent corn snack (placebo) for 2 months. There were no differences between amaranth and placebo on TC and LDL −c, and TG respectively: −8.4 and −5.7% (p = 0.17); −12.3 and −9.7% (p = 0.41) and −0.6 and −7.3% (p = 0.47). However, amaranth snacks significantly reduced high-density cholesterol (HDL−c): −15.2 vs. −4% (p = 0.03). In conclusion, the intake of 50 g of extruded amaranth daily during 60 days did not significantly reduce LDL−c in moderate hypercholesterolemic subjects; furthermore there was a significant reduction in HDL −c. Studies with greater number of subjects and greater quantity of this food are necessary to test the effects of amaranth on lipid metabolism in humans.


Arquivos Brasileiros De Cardiologia | 2017

Persistent Depressive Symptoms are Independent Predictors of Low-Grade Inflammation Onset Among Healthy Individuals

Fábio Gazelato de Mello Franco; Antonio Gabriele Laurinavicius; Paulo A. Lotufo; Raquel Conceicao; Fernando Morita; Marcelo Katz; Mauricio Wajngarten; Jose A.M. Carvalho; Hayden B. Bosworth; Raul D Santos

Background Depressive symptoms are independently associated with an increased risk of cardiovascular disease (CVD) among individuals with non-diagnosed CVD. The mechanisms underlying this association, however, remain unclear. Inflammation has been indicated as a possible mechanistic link between depression and CVD. Objectives This study evaluated the association between persistent depressive symptoms and the onset of low-grade inflammation. Methods From a database of 1,508 young (mean age: 41 years) individuals with no CVD diagnosis who underwent at least two routine health evaluations, 134 had persistent depressive symptoms (Beck Depression Inventory - BDI ≥ 10, BDI+) and 1,374 had negative symptoms at both time points (BDI-). All participants had been submitted to repeated clinical and laboratory evaluations at a regular follow-up with an average of 26 months from baseline. Low-grade inflammation was defined as plasma high-sensitivity C-Reactive Protein (CRP) concentrations > 3 mg/L. The outcome was the incidence of low-grade inflammation evaluated by the time of the second clinical evaluation. Results The incidence of low-grade inflammation was more frequently observed in the BDI+ group compared to the BDI- group (20.9% vs. 11.4%; p = 0.001). After adjusting for sex, age, waist circumference, body mass index, levels of physical activity, smoking, and prevalence of metabolic syndrome, persistent depressive symptoms remained an independent predictor of low-grade inflammation onset (OR = 1.76; 95% CI: 1.03-3.02; p = 0.04). Conclusions Persistent depressive symptoms were independently associated with low-grade inflammation onset among healthy individuals.


Diabetology & Metabolic Syndrome | 2017

Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM)

Marcello Casaccia Bertoluci; Rodrigo Oliveira Moreira; André Arpad Faludi; Maria Cristina de Oliveira Izar; Beatriz D'Agord Schaan; Cynthia M. Valerio; Marcelo Chiara Bertolami; Ana Paula Marte Chacra; Marcus Vinícius Bolívar Malachias; Sérgio Vencio; José Francisco Kerr Saraiva; Roberto Tadeu Barcellos Betti; Luiz Alberto Turatti; Francisco Antonio Helfenstein Fonseca; Henrique Tria Bianco; Martha L. Sulzbach; Adriana Bertolami; João Eduardo Nunes Salles; Alexandre Hohl; Fábio Rógerio Trujilho; Eduardo Gomes Lima; Marcio H. Miname; Maria Tereza Zanella; Rodrigo N. Lamounier; Joäo Roberto de Sá; Celso Amodeo; Antônio Carlos Pires; Raul D Santos

BackgroundSince the first position statement on diabetes and cardiovascular prevention published in 2014 by the Brazilian Diabetes Society, the current view on primary and secondary prevention in diabetes has evolved as a result of new approaches on cardiovascular risk stratification, new cholesterol lowering drugs, and new anti-hyperglycemic drugs. Importantly, a pattern of risk heterogeneity has emerged, showing that not all diabetic patients are at high or very high risk. In fact, most younger patients who have no overt cardiovascular risk factors may be more adequately classified as being at intermediate or even low cardiovascular risk. Thus, there is a need for cardiovascular risk stratification in patients with diabetes. The present panel reviews the best current evidence and proposes a practical risk-based approach on treatment for patients with diabetes.Main bodyThe Brazilian Diabetes Society, the Brazilian Society of Cardiology, and the Brazilian Endocrinology and Metabolism Society gathered to form an expert panel including 28 cardiologists and endocrinologists to review the best available evidence and to draft up-to-date an evidence-based guideline with practical recommendations for risk stratification and prevention of cardiovascular disease in diabetes. The guideline includes 59 recommendations covering: (1) the impact of new anti-hyperglycemic drugs and new lipid lowering drugs on cardiovascular risk; (2) a guide to statin use, including new definitions of LDL-cholesterol and in non-HDL-cholesterol targets; (3) evaluation of silent myocardial ischemia and subclinical atherosclerosis in patients with diabetes; (4) hypertension treatment; and (5) the use of antiplatelet therapy.ConclusionsDiabetes is a heterogeneous disease. Although cardiovascular risk is increased in most patients, those without risk factors or evidence of sub-clinical atherosclerosis are at a lower risk. Optimal management must rely on an approach that will cover both cardiovascular disease prevention in individuals in the highest risk as well as protection from overtreatment in those at lower risk. Thus, cardiovascular prevention strategies should be individualized according to cardiovascular risk while intensification of treatment should focus on those at higher risk.


European Journal of Clinical Pharmacology | 2012

SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia

Paulo Caleb Junior Lima Santos; Ana Carolina Moron Gagliardi; Marcio H. Miname; Ana Paula Marte Chacra; Raul D Santos; José Eduardo Krieger; Alexandre C. Pereira


Rev. bras. hipertens | 2008

Dislipidemia, estatinas e insuficiência renal crônica

Antonio Gabriele Laurinavicius; Raul D Santos


Journal of Nutrition and Food Sciences | 2016

Healthier Body Composition in Vegetarian Men Compared to OmnivorousMen

Julio Cesar Acosta-Navarro; Adriana Midori Oki; Luiza Antoniazzi Gomes de Gouveia; Valeria Hong; Maria Carlos Bonfim; Pedro Acosta-Cardenas; Letícia Romera Picolo; Juliana Nólibos; Gabriela Moraes; Elane Zeferini; Heno Ferreira Lopes; Marcio H. Miname; Luiz Aparecido Bortolotto; Wilson Salgado Filho; Raul D Santos


Rev. Soc. Cardiol. Estado de Säo Paulo | 2007

Estratificação de risco de doença coronária em mulheres

Marcio H. Miname; Otavio Gebara; Raul D Santos

Collaboration


Dive into the Raul D Santos's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Raquel Conceicao

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tanya Keenan

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge